PeptideStack
5.2kquestions
20kanswers
220users

What does TRIUMPH-3 report at the 20 mg dose level?

Asked 13 Jul 2026Modified 1 min agoViewed 4.4k times
16

The particulars: TRIUMPH-3 · 20 mg.

I have the document in front of me and I can read the numbers. What I cannot do is interpret them.

I am reasonably comfortable with statistics and completely uncomfortable with chromatography, or vice versa.

What is the correct interpretation, and what is the common misreading?

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

811 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

444 questions
shareeditfollowflag
TW
askedtare_and_weigh18k2813 Jul 2026
3The timing signature is the useful part. Everything else is confounded. – t_oyelaran 8 months ago
add a comment

1 Answer

Accepted answer first, then by votes
39

Accepted answer

Mechanically, start with the population. The inclusion criteria of the trial determine what its result can be extrapolated to, and the extrapolation people want is usually to a population the trial excluded.

Absolute risk reduction, worked: if the control-arm event rate is 8.0 per cent over the follow-up period and the hazard ratio is 0.80, the treated rate is approximately 6.4 per cent, the absolute risk reduction is 1.6 percentage points, and the number needed to treat is 1 ÷ 0.016 ≈ 63 over that period. A 20 per cent relative reduction and a number needed to treat of 63 are the same finding stated two ways, and only one of them sounds impressive.

Creatinine is a muscle-derived metabolite, so a substantial loss of lean mass lowers serum creatinine and mathematically raises estimated GFR without anything happening to the kidney. If you have lost twenty kilograms, your creatinine-based eGFR is flattering you. Cystatin C is not muscle-dependent and is the measure to use when the two disagree.

SURMOUNT-4 randomised participants after an open-label lead-in to continued tirzepatide or placebo, and the withdrawal arm regained a substantial proportion of the lost weight over the following year[1].

The papers are readable. Read the paper rather than the summary of the paper, especially where the summary is enthusiastic.

edited 16 Aug 2026 by s_bhattacharya — added the placebo-arm figures

shareimprove this answerflag
SB
answered · accepteds_bhattacharya42k3818 Jul 2026
7Worth flagging that this changed in 2025, so older answers on the site are out of date. – marta_okonkwo 9 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.